Protocol · protocol
Hyperbaric oxygen therapy
C+
Headline grade
Cognitive performance in healthy older adults
Evidence type: Randomized trials
The graded dose: The longevity-protocol pattern sold by clinics: 2.0 ATA, 90-minute sessions with air breaks, 60 sessions over about three months (the Tel Aviv protocol). FDA-cleared medical uses (non-healing wounds, radiation injury, carbon monoxide poisoning) follow different, indication-specific protocols and are not what this record grades. Frequency in the evidence: 5 sessions per week. The grade attaches to this dose; below it, the grade does not apply.
The caveat: The popular claim ('HBOT reverses aging') grades D: its entire human basis is one research program's biomarker study. The cognitive finding from the same program is real trial work and grades higher (C+); the distance between the two grades is the distance between a measured outcome and a headline.
Add this to a build, then take the build to your AI.
Time cost
450 minutes / week
Five 90-minute sessions a week during a course, before travel and chamber turnaround time.
Dollar cost
About $2500 / month
$1,500-4,000 during a course (basis: Clinic sessions commonly run $100 to $250; the studied 60-session course totals roughly $6,000 to $15,000 over about three months. No supplement-style monthly cost exists; the figure is the course cost spread over its months.)
Every claim, graded
Each outcome this protocol is claimed to deliver carries its own grade and its own kind of evidence. A strong secondary outcome never launders a weak popular claim: the popular claim prints at its own grade, next to the headline.
Outcomes at a glance
Improves cognitive performance in healthy older adults
Lengthens telomeres and clears senescent cells (the headline longevity claim)
Reverses aging / extends healthspan
Bar length is the outcome's evidence grade on the house scale: A is 4.0 points, B is 3.0, C is 2.0, D is 1.0. The table below carries the evidence type and what the data show for each row.
| Claim | Grade | Evidence | What the data show |
|---|---|---|---|
| Improves cognitive performance in healthy older adults | C+ | rctRandomized trials | One research group's randomized trial of the 60-session protocol reported improved attention and processing speed in healthy adults over 64; the sham design (pressure variation itself) has been criticized, the sample was small, and no independent group has replicated it.Efrati S et al. Hyperbaric oxygen therapy improves cognitive performance in healthy older adults. Aging. 2020. |
| Lengthens telomeres and clears senescent cells (the headline longevity claim) | D+ | rctRandomized trials | A small single-group study (35 adults) from the same research program reported telomere lengthening and senescent-cell reductions after the same protocol; biomarker movement in an uncontrolled-for-this-endpoint design, with no health outcome attached and no independent replication.Hachmo Y et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells. Aging. 2020. |
| Reverses aging / extends healthspan | D | expert | No human trial measures a healthspan or aging outcome for HBOT; the claim is an extrapolation from the biomarker study above, sold at clinic prices.No source exists for this claim at outcome level. |
Dose and response
No dose-response work exists for the longevity use: the 60-session course is a single studied pattern, not a titrated dose, and shorter or cheaper courses are unstudied rather than smaller versions of a proven one.
Equipment that can deliver this dose: clinic chamber access. Delivered in medical or wellness clinics; home mild-pressure bags (about 1.3 ATA) are a different, unstudied intervention and do not inherit this record's grades.
Harms and cautions
Harms live in this ledger, not inside the grade: the grade is evidence for the claimed outcomes in the studied population.
Medication interactions
No medication classes are flagged in this graded record.
Goal conflicts and timing
No goal conflicts in this record.
The studied pattern is five sessions a week for about twelve weeks; weekend and maintenance schedules are clinic invention, not studied patterns.
Population exclusions and other cautions
Barotrauma to the ears and sinuses, the common harm at pressure caution
all users
Untreated pneumothorax is an absolute contraindication to pressurization serious
The contraindication is absolute: the condition rules the therapy out entirely
Oxygen toxicity seizures are rare but real at pressure serious
The studied protocol builds in air breaks against this risk
Claustrophobia ends courses minor
people who cannot tolerate the chamber
The practical harm is financial: the studied course costs thousands, with no maintenance evidence behind it caution
buyers paying for a full course
Can you measure it yourself?
No self-experiment is offered for this record's headline outcomes. FDA-cleared indications for HBOT (diabetic wounds, radiation injury, decompression sickness, carbon monoxide poisoning) are established medicine and are not graded here; this record grades only the longevity and cognitive use clinics sell to healthy buyers.
Goals served
None at the serving floor
Derived from outcomes grading B- or better, never hand-assigned.
Experience gate
advanced and up (safety and cost: a pressurized medical intervention with real contraindications, sold as a multi-thousand-dollar course on single-group evidence.)
Applicability
narrow
Applies only in a narrow, specific situation.
Grades are research summaries, not medical advice. Decisions about your own stack belong with your clinician.
Longevity Lab Report
Protocol news. Graded when it happens.
The grades on this page stay free. The email is the week's longevity and biohacking news in plain English: expert moves, what is working, and new supplements and peptides, each story linked to the grades on this site.
Frequently asked questions
What grade does Hyperbaric oxygen therapy get?
At the studied dose (2.0 ATA oxygen, 90-minute sessions, 60 sessions over about three months), Hyperbaric oxygen therapy grades C+ for cognitive performance in healthy older adults, on randomized trials. The grade attaches to that dose; below it, the grade does not apply.
How much time does Hyperbaric oxygen therapy take each week?
At the graded dose, 450 minutes per week, counted as session time plus standard overhead, travel excluded. Dollar cost: $1,500-4,000 during a course.
Who should not use Hyperbaric oxygen therapy?
Untreated pneumothorax is an absolute contraindication to pressurization. The contraindication is absolute: the condition rules the therapy out entirely. The full harm ledger is on this page, and the medical line applies: decisions about your own stack belong with your clinician.
Sources
- Efrati S et al. Hyperbaric oxygen therapy improves cognitive performance in healthy older adults. Aging, 2020 (cognitive RCT, 60-session protocol). (2020)
- Hachmo Y et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells. Aging, 2020 (telomere and senescence biomarkers, n=35). (2020)
- FDA consumer guidance on hyperbaric oxygen therapy claims.
Changelog
Last reviewed November 2, 2026
- 2026-11-02|Initial grading: hyperbaric oxygen graded as a protocol at the named clinic dose (2.0 ATA, 90 minutes, 60 sessions). Cognitive performance in older adults C+ on a single research group's trial; the telomere headline D+; the aging-reversal claim D. Cost is carried in the record because it is the practical centre of the offer: the studied course runs roughly $6,000 to $15,000.
- 2026-11-02|Integration completions (Growth, at integration): the record's harms prose is carried in the library's harms list shape (five entries, same facts, same order); the record-level goals list is added as the union of its outcomes' goals (cognition, longevity), the derivation every other protocol record carries; and scheduling.spacing takes the library's array shape (empty: the draft's spacing sentence states the course pattern, which the pattern note already carries, and no inter-session spacing rule exists in the graded material). No grade, claim, or source changed.
- 2026-11-02|Correction (Research, same day, superseding the goals part of the integration completion above): a protocol outcome carries goals only when it grades B- or better (the psilocybin precedent, whose C+ clinical outcome carries an empty goal list). Both of this record's graded outcomes sit below that bar, so the C+ cognitive outcome's goals and the D+ telomere outcome's goals are emptied, and the record-level goals list is emptied with them. The record now agrees with its own goals note. Grades, claims, and sources untouched.
- 2026-11-02|Cold-read remedies (Growth, on SEO and Content's findings on the rendered page): the record-level sources take the library's citation-object shape (the draft's own strings and parentheticals, no source added or dropped); sessionsPerWeekRange takes the library's string shape (5); and the harms entries are recast in the library's register, with the absolute contraindication placed as the first serious entry so the page's who-should-not-use answer leads with it. Facts, grades, and severities unchanged.